Giant retinal telangiectasia after ophthalmic plaque radiation therapy Authors: Margarita Labkovich, Paul T. Finger Published: 2026 ABSTRACT PurposeRadiation retinopathy is a known complication of plaque brachytherapy, characterized by progressive retinal vasculature damage. This study describes the clinical course of two cases of late post-radiation giant retinal telangiectasias, discovered in patients treated with radiation for choroidal melanomas.MethodsA single center chart review revealed two patients with giant retinal telangiectasis. Each patient had been treated with palladium-103 (103Pd) plaque brachytherapy for choroidal melanoma. Clinical data revealed their presentation, clinical course and treatment.ResultsGiant retinal telangiectasias were associated with pre-retinal hemorrhages, exudates, and edema occurring 7 and 9 years after irradiation, with macular telangiectasia exhibiting a more fulminant course. It required both laser photocoagulation and periodic intravitreal steroid therapy; both received intravitreal anti-vascular endothelial growth factor injections. Treatment was given based on both telangiectasia activity and other radiation-induced ocular morbidities.ConclusionsGiant retinal telangiectasias are a rare complication that may occur after ophthalmic plaque radiation therapy. Introduction Radiation side-effects have been associated with both intraocular tumor size and location.1, 2, 3 Larger choroidal melanomas typically require more ocular radiation and are thus associated with greater side-scatter to the macula, optic disc, and natural lens. Plaque-treated tumors located in the macula, particularly beneath the fovea or near touching, surrounding, or covering the optic disc, result in a greater incidence of radiation maculopathy and optic neuropathy, respectively.1, 2, 3, 4, 5. This study describes two patients who developed a rare and late complication of plaque radiation therapy. One had a subfoveal and another a circumpapillary melanoma. Both developed giant retinal telangiectasias many years after treatment, defined as an enlarged and dilated retinal vascular lesion larger than one disc diameter in size. Radiation-induced retinal vasculopathy has been attributed to progressive damage and loss of both pericytes and endothelial cells.6, 7, 8, 9, 10 Pericytes are mural cells embedded within the capillary basement membrane that help maintain a low-permeability hydrostatic barrier. In the eye, vision loss results in retinal vascular leakage, extravascular transudation, and progressive perivascular tissue edema.11, 12, 13 Over time, the retina becomes unable to clear this excess fluid, leading to clinically apparent macular edema. As radiation vascular injury progresses, capillary closure develops, producing cotton-wool spots, retinal hemorrhages, and retinal ischemia. Ischemia, in turn, stimulates the release of vascular growth factors, promoting arteriovenous shunt formation and retinal neovascularization.9,12 Endothelial cell death is most closely associated with subclinical vascular closure, which is initially detectable on optical coherence tomography angiography (OCT-A) and later manifests clinically as cotton-wool spots and retinal hemorrhages.11,12 Advanced ischemic retinal vasculopathy is characterized by capillary dropout, vascular sheathing, shunt vessels, and neovascularization. Higher doses of irradiation, particularly in the absence of radiation-modifying (RM) treatment may further accelerate disease progression, resulting in extensive retinal neovascularization and sight-limiting pre-retinal fibrosis. Although clinically apparent manifestations evolve over months to years, subclinical radiation-induced vasculopathy begins within hours of irradiation and is initiated by endothelial cell activation and disruption of intercellular junctions.6,7 Late radiation-induced retinal telangiectasias usually evolve from an acute, high-dose radiation exposure that occurred within the targeted zone. Of interest, similar cutaneous telangiectatic vessels have been reported as a late radiation-related complication, affecting mucosal surfaces of the oral, nasal, gastrointestinal, and genitourinary tracts, as well as subcutaneous soft tissues within the radiation field.6,7,10 This study aims to describe 2 cases of late-onset giant telangiectasias which occurred after plaque brachytherapy for choroidal melanomas. Our research highlights the therapeutic challenges and available treatment strategies to achieve long-term vision preservation and structural stability by reviewing the timeline of each clinical course, imaging findings, and treatment response. Methods We performed a retrospective chart review of N = 200 patients who received 103Pd plaque brachytherapy for choroidal melanoma treatment at least 10 years ago and identified 2 patients with giant retinal telangiectasias that are herein described. All patient health information was processed in accordance with the Health Insurance Privacy and Accountability Act of 1996, and the Declaration of Helsinki. Written consents for publication were obtained. Sourced clinical data included but was not limited to clinical information and imaging (e.g., fundus photographs, macula OCT, and fluorescein angiography). Both choroidal melanomas were diagnosed and treated with 103Pd plaque brachytherapy at The New York Eye Cancer Center. Many years later, giant retinal telangiectasias evolved within the radiation target zone beneath plaque. One melanoma was subfoveal. The other covered the optic nerve and was treated with Finger's slotted plaque technique.4,5 Both were treated with anti-VEGF therapy at early, and visually significant signs of radiation retinopathy.12,13 The subfoveal tumor required subsequent adjuvant steroid and focal laser photocoagulation.14, 15, 16 The endpoints and treatment goals for each patient were to maintain the best corrected visual acuity, reduce injection frequency, and suppress radiation maculopathy and optic neuropathy. Case 1 At initial presentation, a 47-year-old otherwise healthy female was diagnosed with an American Joint Committee on Cancer (AJCC) cT1-category subfoveal choroidal melanoma in her left eye. With 20/20 vision, treatment involved temporary insertion of a103Pd-seeded Collaborative Ocular Melanoma Study (COMS) type plaque for a 7-day duration. Plaque placement required temporary lateral rectus disinsertion with subsequent reattachment. During that time, the retina overlying the tumor apex received 80.36 Gy.5 Five years after irradiation, she developed worsening macular edema and exudates, leading to a decline in her vision to 20/40 (Fig. 1a). Anti-vascular endothelial growth factor (anti-VEGF) treatments were employed, then intensified, and eventually, required polypharmacy with short-acting intravitreal steroid therapy every 3 months. (Fig. 1a).Fig. 1(A) A timeline of the first patient's treatments, corresponding visual acuity at each time point, and clinical findings following 103Pd plaque brachytherapy treatment over 20 years. There is an initial observation period, followed by anti-VEGF therapies, polypharmacy with a short-acting steroid, and long-term suppression with intravitreal fluocinolone 0.19 implant monotherapy. (B) Clinical timeline of the second patient with anti-VEGF monotherapy treatments and respective visual acuity over a period of 20 years. (A) A timeline of the first patient's treatments, corresponding visual acuity at each time point, and clinical findings following 103Pd plaque brachytherapy treatment over 20 years. There is an initial observation period, followed by anti-VEGF therapies, polypharmacy with a short-acting steroid, and long-term suppression with intravitreal fluocinolone 0.19 implant monotherapy. (B) Clinical timeline of the second patient with anti-VEGF monotherapy treatments and respective visual acuity over a period of 20 years. Seven years after undergoing brachytherapy, she started developing a relatively small retinal vascular telangiectasia in the temporal perifoveal retina overlying the tumor residua and edematous macula (Fig. 2a–c). On fluorescein angiography the telangiectatic vessel filled separately and was hyperfluorescent. However, OCT and FA monitoring also revealed slowly progressive macular edema and worsening VA to 20/80 (Fig. 3a–c and 4a-c). Suffering from both RM and an overlying retinal telangiectasia, treatment involved intense monthly anti-VEGF monotherapy over the next 8 years. During that time, RM management was complex but included continuous periodic anti-VEGF therapy, one focal laser leading to telangiectasia-related hemorrhage, and four intravitreal triamcinolone acetonide (Triesence®, Harrow, Nashville, Tennessee, USA) injections to a visual acuity of 20/200 (Fig. 1a and 2d-e).Fig. 2Fundus photos of the left eye after plaque treatment in patient 1 (2a), first evidence of radiation retinopathy indicated by a blue arrow at 5 years after plaque treatment (2b), initial telangiectasia formation at 7 years after plaque treatment (2c) with continuous progression at 19 years post plaque (2d) and 20 years post plaque brachytherapy (2e). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)Fig. 3Fluorescein angiography (FA) of patient 1 over time. (3a) Initial FA after plaque treatment. (3b) FA at the time of the radiation retinopathy formation. (3c) Note that 7 years after plaque, the telangiectasia can be seen as a mild vasculopathy with leakage (yellow arrow). (3d) 19 years after plaque, the telangiectasis is starting to accumulate fluorescein dye (yellow arrow). (3e) though the macular edema is suppressed and the telangiectasia stabilized, there is increased retention of fluorescein dye pointed to by a yellow arrow. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)Fig. 4A sagittal section OCT of the macula over time as seen in patient 1. (4a) 5 years after plaque, showing initial radiation retinopathy. (4b) 7 years after plaque with florid radiation maculopathy is characterized by thickening and intraretinal fluid, marking the presence of radiation maculopathy with a telangiectasia demarcated by a yellow arrow. (4c and d) Images at 19 and 20 years after treatment show a reduction in macular thickness and consolidation of the retinal telangiectasia (yellow arrow). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) Fundus photos of the left eye after plaque treatment in patient 1 (2a), first evidence of radiation retinopathy indicated by a blue arrow at 5 years after plaque treatment (2b), initial telangiectasia formation at 7 years after plaque treatment (2c) with continuous progression at 19 years post plaque (2d) and 20 years post plaque brachytherapy (2e). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) Fluorescein angiography (FA) of patient 1 over time. (3a) Initial FA after plaque treatment. (3b) FA at the time of the radiation retinopathy formation. (3c) Note that 7 years after plaque, the telangiectasia can be seen as a mild vasculopathy with leakage (yellow arrow). (3d) 19 years after plaque, the telangiectasis is starting to accumulate fluorescein dye (yellow arrow). (3e) though the macular edema is suppressed and the telangiectasia stabilized, there is increased retention of fluorescein dye pointed to by a yellow arrow. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) A sagittal section OCT of the macula over time as seen in patient 1. (4a) 5 years after plaque, showing initial radiation retinopathy. (4b) 7 years after plaque with florid radiation maculopathy is characterized by thickening and intraretinal fluid, marking the presence of radiation maculopathy with a telangiectasia demarcated by a yellow arrow. (4c and d) Images at 19 and 20 years after treatment show a reduction in macular thickness and consolidation of the retinal telangiectasia (yellow arrow). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) Remarkably, three consecutive fluocinolone acetonide intravitreal implants (Iluvien®, Alimera Sciences, Baudette, Minnesota, USA) have achieved sustained suppression of both her radiation maculopathy and giant retinal telangiectasia. At the most recent follow-up, years after radioactive plaque therapy, macular edema had decreased and visual acuity remained stable at 20/200. Based on this durable response, treatment was transitioned to fluocinolone acetonide implant monotherapy. Implants administered at 15, 17, and 20 years after the initial brachytherapy treatment resulted in improved macular edema and sustained control of retinal telangiectasia, with best-corrected visual acuity remaining stable at 20/200 (Fig. 2b–c, 3b–d, and 4b–c). Both fluorescein angiography and macular optical coherence tomography (OCT) showed reduced leakage and resolving macular edema. (Fig. 3d and e and 4d). Case 2 A 33-year-old otherwise healthy female was referred to The New York Eye Cancer Center, where she was diagnosed with an AJCC cT-3 circumpapillary choroidal melanoma in her right eye. With a pre-operative visual acuity of 20/25, treated by temporary insertion of a Finger's slotted 103Pd-seeded gold plaque over a 7-day duration. The tumor apex received an apical prescription dose of 89.41 Gy.5 Two years after plaque brachytherapy, she started developing radiation retinopathy with macular edema and exudates, which was initially suppressed with continual periodic intravitreal anti-VEGF therapy (Fig. 1b). Of note, though anti-VEGF therapy allowed her to maintain 20/50 vision for 3 years following plaque therapy, she was lost to follow-up and did not receive treatment for 16 months, causing her vision to drop to 20/250. Therefore, it was restarted on monthly anti-VEGF injections and recovered to 20/125 (Fig. 1b). Nine years after initial plaque treatment, she developed a juxtapapillary dilated and tortuous retinal telangiectasia (Fig. 5a–c and 6a-c). She was maintained on continuous periodic anti-VEGF monotherapy, preserving her vision at 20/100. At most recent follow-up which was 20 years after radioactive plaque brachytherapy, her vision was 20/125 (Fig. 1b).Fig. 5Fundus photograph over time in patient 2. (5a) Tumor after plaque therapy treatment. (5b) First evidence of radiation retinopathy. (5c) A fundus 9 years after treatment with telangiectasia vessel formation (blue arrow). (5d) Patient is on anti-VEGF therapy at this time. Note the giant retinal telangiectasis (blue arrow), suppressed radiation optic neuropathy, and macular atrophy. (5e) At her most recent follow up visit, note the enlarging giant retinal telangiectasia (blue arrow). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)Fig. 6Fluorescein angiography (FA) timeline of patient 2. (6a) FA after plaque therapy. (6b) At the time when radiation retinopathy was first seen. (6c) 9 years after treatment with marked tumor darkening and regression (yellow arrow). (6d) On anti-VEGF therapy, note the giant retinal telangiectasis (yellow arrow), suppressed radiation optic neuropathy, and macular atrophy. (6e) At her most recent follow up visit (yellow arrow). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) Fundus photograph over time in patient 2. (5a) Tumor after plaque therapy treatment. (5b) First evidence of radiation retinopathy. (5c) A fundus 9 years after treatment with telangiectasia vessel formation (blue arrow). (5d) Patient is on anti-VEGF therapy at this time. Note the giant retinal telangiectasis (blue arrow), suppressed radiation optic neuropathy, and macular atrophy. (5e) At her most recent follow up visit, note the enlarging giant retinal telangiectasia (blue arrow). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) Fluorescein angiography (FA) timeline of patient 2. (6a) FA after plaque therapy. (6b) At the time when radiation retinopathy was first seen. (6c) 9 years after treatment with marked tumor darkening and regression (yellow arrow). (6d) On anti-VEGF therapy, note the giant retinal telangiectasis (yellow arrow), suppressed radiation optic neuropathy, and macular atrophy. (6e) At her most recent follow up visit (yellow arrow). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) Since the initial diagnosis, her giant retinal telangiectasia has remained stable with anti-VEGF therapy. (Fig. 5d and e and 6d-e). The patient's visual acuity has declined due to progressive macular atrophy. In this case, the giant telangiectasia was extramacular and thus less likely to cause vision loss. In these cases, both patients developed giant telangiectasias in different parts of the retina, affecting their treatment strategies and risks to vision. Discussion Herein, we describe two cases of giant retinal telangiectasias that occurred within the targeted zone after 103Pd plaque brachytherapy for a choroidal melanoma. While intraretinal micro-angiopathy, including anastomoses, retinal artery and vein occlusions, as well as small retinal telangiectasias have been associated with radiation retinopathy, giant retinal telangiectasias have not been defined and there are no existing guidelines to manage this vision-threatening complication. Our experience with Case #1 suggests that the giant perifoveal telangiectasia was associated with macular hemorrhaging and macular edema even after anti-VEGF injections and focally targeted laser.12,16 Short-acting steroids improved but were insufficient to stabilize the leakage.14 However, long-term periodic fluocinolone acetonide implants have resulted in sustained control of its vascular permeability and macular edema.15 In contrast, our experience with the second case revealed that continuous periodic anti-VEGF monotherapy was sufficient. Perhaps, it was due to the giant telangiectasia's nasal peripapillary location. In this case, her changes in vision were attributed to incomplete compliance with continuous intravitreal anti-VEGF therapy and RM-associated perifoveal atrophy. Although the exact mechanisms underlying giant retinal telangiectasias remain poorly understood, accurate treatments such as laser photocoagulation, intravitreal and subtenon's triamcinolone injections, as well as intravitreal anti-VEGF injections are effective and are continuously studied in different stages of radiation retinopathy/maculopathy.12, 13, 14, 15, 16. The weaknesses of this study are the limited number of cases found with giant retinal telangiectasias. Furthermore, from the two cases, we cannot postulate how radiation dose or dose rate plays a role in their formation. We did not use indocyanine green angiographic testing to further characterize the extent of these vascular abnormalities. The strengths of this study include the remarkable multidecade, longitudinal, and mostly uninterrupted follow-up of both patients. This attribute supports our findings regarding how each patient responded to treatment. Each case was closely monitored according to The New York Eye Cancer Center's screening guidelines, and the injection frequency and treatment escalation were modulated by examination of the optic disc and macula with ophthalmoscopy, fundus photography, fluorescein angiography, OCT, and visual acuity. Although each patient in this study received an individualized treatment approach, the collective cases provide valuable insight into the management of post-radiation vasoproliferative disorders and the temporal patterns of response to various therapies.17,18 Future prospective studies or pooled analyses of larger cohorts are needed to better elucidate the mechanisms underlying radiation-associated giant retinal telangiectasia and to more clearly define the effectiveness of treatments aimed at limiting exudation and disease progression. Conclusion This case report discusses two giant telangiectasias seen 7and 9 years after 103Pd plaque radiation therapy. One was relatively indolent, extra-macular, but progressed in size despite continuous periodic intravitreal anti-VEGF treatment. The other involved the perifoveal macula and was associated with significant exudation and macular edema, requiring additional interventions. Only the application of long acting fluocinolone acetonide was associated with regression of one giant retinal telangiectasia. Ethics approval and informed consent statements This study was performed in accordance with the Declaration of Helsinki. The analysis of patient health information and relevant records was conducted in compliance with the Health Insurance Portability and Accountability Act. Informed consent was obtained to include relevant health data and imaging. Claims of priority statement A literature review conducted on February 23rd, 2026, using PubMed and Google Scholar with the keywords “giant retinal telangiectasia” did not reveal any reports of giant telangiectasis after choroidal melanoma treatment with plaque brachytherapy. Artificial intelligence The authors declare that an artificial intelligence application was not used to assist with the data collection, writing or review of this manuscript. Funding statement The Eye Cancer Foundation supported this research and its publication. CRediT authorship contribution statement Margarita Labkovich: Data curation, Formal analysis, Investigation, Writing – original draft. Paul T. Finger: Conceptualization, Methodology, Supervision, Writing – review & editing. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.